About addex therapeutics ltd. - ADXN
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
ADXN At a Glance
Addex Therapeutics Ltd.
9, Chemin des Mines
Geneva, Geneve (Geneva) 1202
| Phone | 41-22-884-15-55 | Revenue | 208.14K | |
| Industry | Pharmaceuticals: Major | Net Income | -8,101,574.32 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ADXN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 33.187 |
| Price to Book Ratio | 1.262 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.445 |
| Enterprise Value to Sales | 23.46 |
| Total Debt to Enterprise Value | 0.009 |
ADXN Efficiency
| Revenue/Employee | 69,381.041 |
| Income Per Employee | -2,700,524.774 |
| Receivables Turnover | 8.209 |
| Total Asset Turnover | 0.021 |
ADXN Liquidity
| Current Ratio | 1.397 |
| Quick Ratio | 1.397 |
| Cash Ratio | 1.367 |
ADXN Profitability
| Gross Margin | 95.099 |
| Operating Margin | -1,628.255 |
| Pretax Margin | -1,637.247 |
| Net Margin | -3,892.309 |
| Return on Assets | -83.214 |
| Return on Equity | -98.784 |
| Return on Total Capital | -136.097 |
| Return on Invested Capital | -98.357 |
ADXN Capital Structure
| Total Debt to Total Equity | 0.729 |
| Total Debt to Total Capital | 0.723 |
| Total Debt to Total Assets | 0.545 |
| Long-Term Debt to Equity | 0.567 |
| Long-Term Debt to Total Capital | 0.563 |